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Background: Sulphadoxine-pyrimethamine (SP) has been in use for the treatment of uncomplicated falciparum
malaria in Malaysia since the 1970s and is still widely employed in spite of widespread clinical resistance. Resistance
to SP is known to be mediated by mutations in the pfdhfr and pfdhps genes. The aim of the present study was to
investigate the distribution of pfdhfr and pfdhps gene polymorphism in Plasmodium falciparum field isolates from
Kalabakan, Sabah, in northern Borneo.
Methods: A total number of 619 individuals were screened from 23 study sites of which 31 were positive for P.
falciparum. Analysis of restriction fragment length polymorphisms (RFLP) was used to identify polymorphism in the
pfdhfr and pfdhps genes at positions 16, 51, 59, 108, 164 and 437, 540, 581, respectively.
Results: All samples had at least one mutation in each of the genes associated with drug resistance. The
prevalence of pfdhfr 59arg, 164leu and 108asn were 100%, 80.65% and 58.06%, respectively. Pfdhps mutants 437gly
and 581gly accounted for 100% and 74.19% respectively. In pfdhfr, the most common mutant genotypes were
combination 59arg + 164leu (22.58%) and 59arg + 108asn + 164leu (51.61%). In pfdhps the most common genotype
was 437gly + 581gly (74.19%). One individual (3.22%) harboured parasites with four pfdhfr (16 val + 59arg + 108asn +
164leu) and two pfdhps (437gly + 581gly) mutations. The highest quintuple pfdhfr/pfdhps (41.94%) was three pfdhfr
(59arg + 108asn + 164gly) and two pfdhps (437gly + 581gly).
Conclusion: The data suggest a high prevalence of genetic variations conferring resistance to SP which can predict
treatment failure before becoming clinically evident. In areas like this, the use of SP may no longer be indicated.
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Malaysia is in the pre-elimination phase of the malaria
elimination programme [1]. Malaysia is fully committed to
controlling malaria, providing good infrastructure for con-
trol which dates back to the programme’s implementation
in 1961. The impact of the malaria eradication programme
has resulted in a major reduction of malaria cases from
243,870 in 1961 to 44,226 in 1980 [1,2] and has provided
the basis for the subsequent malaria control programme
which began in 1982. In 2010, the National Malaria* Correspondence: noorraina@gmail.com
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reproduction in any medium, provided the orControl Programme was re-oriented from control to
elimination, with the implementation of the “Malaria
Elimination Programme”. This is in line with the global
vision of malaria elimination and the aim of achieving
malaria elimination status in Peninsular Malaysia by
2012 and Malaysian Borneo by 2020 [3,4].
The majority of the malaria cases reported in Malaysia
in 2012 originated from two states in northern Borneo,
Sabah (45%) and Sarawak (29%) (Vector Borne Disease
Control 2012, unpublished data). This can largely be
attributed to inaccessibility, climate and migration across
the nearby border with Indonesia and results in a highly
heterogeneous distribution of vector and parasite species
as well as drug resistance patterns.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elimination efforts in the region [5,6]. Sulphadoxine-
pyrimethamine (SP) has been in use for the treatment of
uncomplicated falciparum malaria in Malaysia since the
1970s. It is used in remote areas for uncomplicated
chloroquine-resistant Plasmodium falciparum infections
for outpatient as well as inpatient malaria cases. In spite
of clinical resistance reported in some places, this com-
bination is still widely employed [7-10].
The genetic background of SP resistance is better docu-
mented than any other anti-malarial drug. Mutations in
the dihydropteroate synthase (dhps) and dihydrofolate
reductase (dhfr) genes, both coding for essential enzymes
in the folate biosynthesis pathway, mediate drug resistance
to SP [11-13]. Pfdhfr codon ser108asn is likely to play a
key role in pyrimethamine resistance with mutations at
51ile, 59arg and 164 leu modulating the level of resistance
[14]. The pfdhfr triple mutation 51ile, 59arg and 108asn,Table 1 The primer pairs, the cycling temperature and restric
pfdhfr
Second-round PCR for pfdhfr
region containing the
polymorphism
Cycling temperature Size (bp)
F: 5′-GAA- 94°C for 2 min; 326
ATG-TAA-TTC- 94°C for 1 min,
CCT-AGA-TAT- 45°C for 1 min,





TTA-GAG- 94°C for 1 min,
CTTC-3′ 45°C for 1 min,
72°C for 1 min Further
extension 72°C for 10 min







The fragment sizes of wild type and mutant are indicated.has been shown to be associated with SP treatment failure,
regardless of pfdhps genotype. Study have shown that
findings in vitro may have indication or consistent with
reports of failure treatment in the country [15-17].
Sulphadoxine resistance in P. falciparum is associated
with mutations at five pfdhps codons; 436ala/phe, 437gly,
540glu, 581gly and 613ser [18-20]. A strong indicator for
SP treatment failure is the quintuple mutations in three
pfdhfr codons (108asn + 51ile + 59arg) and two pfdhps co-
dons (437gly + 540glu) [21,22].
In spite of a massive reduction in malaria cases in
Malaysia, the drug resistance situation remains poorly
documented [9]. Particularly in times of pre-elimination, a
better understanding of the epidemiology of drug resist-
ance has become vital for the region. The aim of the
present study was therefore to investigate the distribution
of pfdhfr and pfdhps gene polymorphism in P. falciparum




















ala NlaIII 53, 93, 376 146, 245
16
val
asn Tsp5091 55, 65, 120, 55, 65, 120,
51 153 218
ile
ser BsrI 522 190, 332
108
asn
ile Dra I 107, 171, 107, 143,
164 245 245
leu
Table 2 The primer pairs, the cycling temperature and restriction enzymes used in detection of gene polymorphism on
pfdhps














K: 5′ TGC-TAG- 94°C for 3 min 438 ala Ava II 438 404
TGT-TAT-AGA- 437
TAT-AGG-ATG- 40 cycles of gly
AGC-ATC-3′ 94°C for 1 min
at 45°C for 45 lys FokI 438 85, 320




72°C for 10 min
glu
L: 5′-ATA- 94°C for 2 min, 161 ala BstUI 105 138
GGA-TAC-TAT- 45°C for 2 min, 581
TTG-ATA-TTG- 72°C for 1 min gly




followed by 35 cycles 94°C for
1 min; 45°C for 1 min, 72°C for
1 min 30 sec.
Further extension at 72°C for
10 min
The fragment sizes of wild type and mutant are indicated.
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Study area and sample collection
The study was conducted between 2008 and 2009 in
Kalabakan, 100 km from Tawau, in Sabah, bordering
East Kalimantan. Samples were collected by active case
detection in villages, logging and road construction
camps within a radius of 50 to 80 km from Kalabakan.
Kalabakan contributes most of the malaria cases in
Sabah and was reported to have the highest number of
malaria cases in 2008 and 2009 with 21.54% and 22.79%,
respectively, of the total number of cases in Sabah. At
the time this study was conducted, SP was the official
first-line treatment for uncomplicated falciparum mal-
aria and it remains widely used.
The study protocol was reviewed and approved by the
institutional review board of the Institute for Medical
Research, Kuala Lumpur and the Medical Review and
Ethics Committee of the Ministry of Health, Malaysia.
Individuals who consented to participate in the study
were screened for malaria using rapid diagnostic tests
(RDT) (Paramax- 3TM; Zephyr Biomedicals, India). In
addition, blood films for malaria parasite (BFMP) were
prepared to determine parasite density. All study partici-
pants diagnosed positive for malaria infection by RDT
had 500 μl of whole blood collected by venepuncture.
Blood was then spotted on 3MM Whatman filter paper.
The filter paper was allowed to dry completely, transferred
into individual plastic bags, labelled, and transported to
the Institute for Medical Research in Kuala Lumpur whereconfirmation of species by PCR and genotype analysis was
conducted. Speciation for Plasmodium vivax, P. falcip-
arum, Plasmodium malariae and Plasmodium knowlesi
was undertaken using a modified version of published
method [23,24].
DNA extraction
DNA from filter paper was extracted using QIAampTM
DNA mini kit (QIAmp; QIAGEN, Hilden, Germany),
according to the manufacturer’s instructions (dried
blood spots protocol) with the only modification being
an adjustment of the elution buffer volume used to elute
the DNA. DNA samples were then kept at −20°C until
further processing.
Genotyping of pfdhfr and pfdhps by PCR-RFLP
PCR reaction and the restriction fragment polymorphism
protocol (PCR-RFLP) were used for the detection of muta-
tion on pfdhfr as described elsewhere [25] with some
modification to DNA and primer concentrations. The first
round PCR reaction mixture consisted of 50 ng of gen-
omic DNA, 0.20 μM of each primer, 200 μM dNTPs,
1.5 mM MgCl2, and 2.5 U of Taq polymerase in a final re-
action volume of 50 μl. Two microlitres of the amplified
product from the first PCR were subjected to two sets of
secondary round PCR reaction mixtures containing
0.20 μM of each primer, 200 μM dNTPs, 2.0 mM MgCl2,
and 2.5 U Taq polymerase. The PCR reaction used





















Figure 1 PCR-RFLP of the pfdhfr gene, amplified region of M3-
F/primers. BsrI cleaved the 522 bp fragment into 190 and 332 bp
indication of 108asn mutation (A). DraI detect 164leu mutations
producing 28, 107, 171 and 245 bp fragments for wild type and 107,
143 and 245 bp for mutant (B). Digestion with NlaIII produce 53, 93
and 376 bp for wild type and 146 and 245 bp for mutant at codon
16 (C) and digestion with Tsp5091 yielded 55, 65, 120, and 153 bp
fragments for wild type and 55, 65, 120 and 218 bp fragments for
mutant for detection on polymorphism at codon 51 (D). Lane L:
DNA ladder of Agilent DNA 1000 Kit (Agilent Technologies,
Molecular Probes Inc, USA), The controls are in Lane 1 and 2:
A: Lane 1: Plasmodium falciparum KI strain (mutant); Lane 2: P.
falciparum T9.96 strain (wild type); Lane 3–9: field samples from
Kalabakan; well 10: PCR negative control (no DNA was added to the
PCR reaction). B and C: Lane 1: Plasmodium falciparum KI strain (wild
type); Lane 2: P. falciparum T9.96 strain (wild type); Lane 3–9: field
samples from Kalabakan; well 10: PCR negative control (no DNA was
added to the PCR reaction). D: Lane 1: Plasmodium falciparum KI
strain (wild type); Lane 2: P. falciparum W2 strain (mutant) Lane 3–9:
field samples from Kalabakan; well 10: PCR negative control (no DNA











Figure 2 PCR-RFLP of the pfdhfr gene, amplified region of M4-F
primers. The 326 bp fragment was cut by Alu I into 180 and 118 bp
fragments, indications for wild type ser108 and 299 bp for mutant
(A). BstNI digested only mutant allele into 145 and 181 bp indicates
mutation 108thr. All the tested samples showed wild type (B).
Reaction with XmnI produced fragment 163 and 189 bp for wild
type; and 26, 137 and 163 bps for 59arg mutation (C). Lane L: DNA
ladder of Agilent DNA 1000 Kit (Agilent Technologies, Molecular
Probes Inc, USA), The controls are in Lane 1 and 2:
A: Lane 1: Plasmodium falciparum KI strain (mutant); Lane 2: P.
falciparum T9.96 strain (wild type); Lane 3–9: samples from
Kalabakan; Lane 10: PCR negative control (no DNA was added to the
PCR reaction). B: Lane 1: Plasmodium falciparum KI strain (wild type);
Lane 2: P. falciparum T9.96 strain (wild type); Lane 3–9: samples from
Kalabakan; Lane 10: PCR negative control (no DNA was added to the
PCR reaction). C: Lane 1: Plasmodium falciparum KI strain (mutant);
Lane 2: P. falciparum T9.96 strain (wild type); Lane 3–9: samples from
Kalabakan; Lane 10: PCR negative control (no DNA was added to the
PCR reaction).
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M3-F/amplifying a 522 bp fragment containing ala16val,
asn51ile, ser108asn and ile164leu (Table 1).
Table 3 PCR-RFLP* findings of polymorphism on the
pfdhfr and pfdhps gene from samples (n = 31) collected in
Kalabakan, Sabah
pfdhfr pfdhps
Codons ala asn cys ser ser ile ala lys ala
16 51 59 108 108 164 437 540 581
val ile arg asn thr leu gly glu gly
% Mutation 16.12 0 100 58.06 0 80.64 100 0 74.19
Wild-Type 83.87 100 0 49.94 100 19.35 0 100 25.8
* PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism
§ Alanine = ala, Valine = val, Asparagine = asn, Isoleucine = ile, Cysteine = cys,
Arginine = arg, Serine = ser, Threonine = thr, Leucine = leu, Glycine = gly, Lysine =








Figure 3 PCR-RFLP of pfdhps gene. Amplified region of K-K/
primers was targeted to ala437gly with AvaII and lys540glu with
FokI, showed 404 bp (mutant) and 438 bps (wild type) respectively
(A, B). Reaction of L-L/amplified region with BstUI showed presence
of 581gly mutation with a 138 bp fragment and wild type ala581
producing a 105 bp (C). Lane L: DNA ladder of Agilent DNA 1000 Kit
(Agilent Technologies, Molecular Probes Inc, USA). The controls are
in Lane 1 and 2: A: Lane 1: Plasmodium falciparum 3D7 strain
(mutant); Lane 2: P. falciparum K1 strain (mutant); B: Lane 1:
Plasmodium falciparum K1 strain (wild type); Lane 2: P. falciparum
T9.96 strain (wild type); C: Lane 1: Plasmodium falciparum K1 strain
(mutant); Lane 2: P. falciparum W2 strain (wild type). Lane 3–10:
samples from Kalabakan; Lane 11: PCR negative control (no DNA
was added to the PCR reaction).
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of mutation in the pfdhps gene as described previously
[25] with modification on the cycling temperature for the
second-round PCR, DNA and primers concentration. The
first round PCR was performed using the primer sets R1-
R2, followed by two sets of second-round PCR using K-K/
and L-L/primers pair (Table 2). The PCR reaction used
primers K-K/amplifying a 438 bp fragment containing
ala437gly and lys540glu, and primers L-L/amplifying a
161 bp fragment containing ala581gly. The PCR and the
nested PCR reactions used the same final concentrations
as in the first round PCR carried out for pfdhfr.
The products of the secondary PCR containing the
polymorphic region were subjected to enzyme digestion
for the detection of mutations at the various sites. The
enzyme digestions were conducted according to manu-
facturer’s instructions (New England Biolabs, Beverly,
MA). The details of primer sequences, cycling tempera-
tures, restriction enzyme digestion and fragment sizes
for each codon are shown in Tables 1 and 2. DNA of la-
boratory strain P. falciparum 3D7, K1, W2 and T9.96
were included in each reaction of PCR and RLFP and
served as positive and negative controls. Water was used
to replace the DNA template for the negative control.
Analysis of PCR-RFLP products using the Agilent 2100
Bioanalyzer
The PCR-RFLP products were analysed using the Agilent
2100 Bioanalyzer and the Agilent DNA 1000 Kit (Agilent
Technologies, Molecular Probes Inc, USA). The proce-
dures were conducted according to manufacturer’s in-
structions (Agilent Technologies, Molecular Probes Inc,
USA). The results were then viewed and analysed using
the Agilent 2100 software.
Results
Sample collection
A total number of 619 individuals were enrolled and
screened at 23 sites. Fifty-eight (9.37%) (95% [CI] = 7.07-
11.67%) tested positive for malaria, 5% (95% [CI] = 3.28-6.72%) were positive for P. falciparum. The pfdhfr and
pfdhps gene were successfully amplified on all the 31 sam-
ples from Kalabakan. These samples were then included
in PCR-RFLP analysis for the determination of the preva-
lence of mutations in the pfdhfr and pfdhps genes.
Pfdhfr mutant genotype
PCR and RFLP products were analysed by Agilent 2100
Bioanalyzer and the Agilent DNA 1000 Kit for the detec-
tion of mutations in the pfdhfr gene (details in Figures 1
and 2). Based on PCR-RFLP findings 100%, 80.64%
(95% [CI] = 66.74-94.56%), and 58.06% (95% [CI] =
40.69-75.43%) were classified as pfdhfr mutants 59arg,
Table 4 Frequency of mutant genotype for the pfdhfr and
pfdhps genes in samples from Kalabakan, Tawau
Gene Mutant genotype % (95% [CI])
pfdhfr 59arg 6.45 (95% [Cl] = −2.2-15.1%)
16 val, 59arg 9.67 (95% [Cl] = −0.73-20.07%)
59arg, 108asn 3.23 (95% [Cl] = −2.99-9.45%)
59arg, 164leu 22.58 (95% [Cl] = 7.86-37.3%)
59arg, 108asn, 164leu 51.61 (95% [Cl] = 34.02-69.2%)
16 val, 59arg, 164leu 3.23 (95% [Cl] = −2.99-9.45%)
16 val, 59arg, 108asn, 164leu 3.23 (95% [Cl] = −2.99-9.45%)
pfdhps 437gly, 581gly 74.19 (95% [CI] = 58.79 – 89.59%)
*Valine = val, Asparagine = asn, Arginine = arg, Leucine = leu, Glycine = gly.
Abdullah et al. Malaria Journal 2013, 12:198 Page 6 of 8
http://www.malariajournal.com/content/12/1/198164leu and 108asn, respectively (Table 3). Mutation at
codon 164 and 108 has been identified as strong deter-
minant for pyrimethamine resistant. No mutation was
detected at codon 51.
Pfdhps mutant genotype
The most common mutations of the pfdhps gene (details
in Figure 3) were observed at 437gly (100%) and 581gly
(74.19%) (95% [CI] = 58.79–89.59%) which are commonly
associated with sulphadoxine resistance (Table 3). No mu-
tation was observed at codon 540.
Pfdhfr/pfdhps mutant genotype combination
Five different mutant genotypes related to the pfdhfr
gene (Table 4) were identified. The three most common
combinations were 59arg + 108asn + 164leu (51.61%)
(95% [CI] = 34.02%-69.2%) and 59arg + 164leu (22.58%)
(95% [CI] = 7.86%-37.3%). The rest of the genes, 25.81%
(95% [CI] = 10.41% to 41.21%), existed either on its own
or in combination with the other genes (Table 4). Pfdhps
mutant genotypes combined 437gly + 581gly (74.19%)Table 5 The frequency of mutant genotypes combining muta
during the study in Kalabakan (n = 31)

















val asn arg asn ser leu gly L
val asn arg ser ser leu gly L
ala asn arg asn ser leu gly L
val asn arg ser ser ile gly L
ala asn arg ser ser leu gly L
ala asn arg ser ser ile gly L
ala asn arg ser ser ile gly L
ala asn arg ser ser leu gly L
ala asn arg asn ser leu gly L
* Alanine = ala, Valine = val, Asparagine = asn, Isoleucine = ile, Cysteine = cys, Arginin
Glutamic acid = glu.
§ Mutation is represented by amino acid in italic bold.(95% [CI] = 58.79%-89.59%) (Table 4). When combining
pfdhfr and pfdhps mutations, there was one parasite
isolate (3.22%) (95% [CI] = −2.99%-9.43%) harbouring
four pfdhfr (16 val + 59arg + 108asn + 164leu) and two
pfdhps (437gly + 581gly) mutations (Table 5). The most
commonly found mutant genotype combining pfdhfr and
pfdhps linked three pfdhfr mutations 59arg + 108asn +
164leu with two pfdhps mutations 437gly + 581gly with
41.94% (95% [CI] = 24.57%- 59.31%) (Table 5).
Discussion
The study report the prevalence of mutations in the pfdhfr
and pfdhps genes in P. falciparum field isolates collected
from individuals in Kalabakan, Sabah (Northern Borneo).
This region remains the focus of P. falciparum infection in
a country that has reached pre-elimination and is striving
for malaria elimination in the coming years. SP has been
used extensively in the region for more than 30 years, as
first-line drug until 2010 [26]. This is surprising as SP treat-
ment failures have been reported from Malaysia as early as
1982 [7]. By the late 1990s, SP resistance had reached
47.4% in Peninsular Malaysia [8] and 29.4% in Tawau,
Sabah [9] and first evidence of the molecular background
of SP resistance in Malaysia came from a study conducted
on mainland Malaysia and Borneo reported in 2001 [27].
The findings of the study indicate that all samples col-
lected harbour at least one of the markers known to be
involved in SP resistance on both the pfdhfr as well as
the pfdhps gene. Without exception all samples (100%)
had the pfdhps mutation 437gly, which is a common ob-
servation in areas where SP is widely used. Earlier stud-
ies suggest that its presence alone or in combination
with 540glu is predictive of early SP treatment failure
[28,29]. The 540glu is typically found together with
437gly, particularly in Africa [30,31]. However, thetions in the pfdhfr and pfdhps genes in isolates collected









ys gly 3.22 (1/31) 4dhfr, 2 dhps
ys gly 3.22 (1/31) 3dhfr, 2 dhps
ys gly 41.94 (13/31) 3dhfr, 2 dhps
ys gly 9.67 (3/31) 2dhfr, 2dhps
ys gly 16.12 (5/31) 2dhfr, 2dhps
ys gly 3.22 (1/31) 1dhfr, 2dhps
ys ala 3.22 (1/31) 1dhfr, 1dhps
ys ala 6.45 (2/31) 2dhfr, 1dhps
ys ala 12.90 (4/31) 3dhfr, 1dhps
e = arg, Serine = ser, Threonine = thr, Leucine = leu, Glycine = gly, Lysine = lys,
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harboured the pfdhps 437gly mutation together with
581 gly (74.19%) rather than 540glu. In fact, the studies
indicate the complete absence of the 540glu mutation in
the patient samples. Both combinations have been asso-
ciated with sulphadoxine resistance [32,33]. The findings
for 581gly also confirm earlier reports from the region
[27]. In spite of extensive use of the drug there were sur-
prisingly few changes in the epidemiology of pfdhps and
pfdhfr mutations within these seven years.
The other mutation that seems to affect virtually all P.
falciparum parasite samples in the region is 59arg
(Table 3). This mutation is believed to modulate pyrimeth-
amine resistance [21,34]. A study conducted in Burkino
Faso, showed that pfdhfr 59arg, with 51ile and 108asn is
an important marker for SP treatment failure [35].
Another study from Mozambique suggested that the two
mutations at pfdhfr 59arg and pfdhps 437gly were enough
to predict SP treatment failure [36].
The study suggests that there are two predominant
pfdhfr mutation genotypes; 59arg + 164leu (22.58%) and
59arg + 108asn + 164leu (51.61%). There was not a single
quadruple mutant (51ile + 59arg + 108asn + 164leu) in the
samples, which is considered to be an indication of the
highest levels of resistance to pyrimethamine [37]. Similar
to the 540glu mutation in pfdhps, this study did not
identify any sample with the 51ile mutation. However,
Dokomajilar et al. suggested that 59arg, even in the ab-
sence of 51ile, may be more important as a marker for
pyrimethamine resistance [35].
However, the results observed the presence of a sextuple
mutation consisting of four pfdhfr (16val, 59arg, 108asn
and 164leu) and two pfdhps (437gly, 581gly) mutations in
a single individual from loggers’ camps near the border of
Kalabakan to East Kalimantan. There were two sets of
three pfdhfr and two pfdhps mutation (a quintuple) ob-
served in the samples; a mutation genotype consisting
of 59arg + 108asn + 164le + 437gly + 581gly, making up
41.94% of the samples and 16 val + 59arg + 164leu +
437gly + 581gly, which was found in a single sample only.
The association of molecular findings with clinical treat-
ment response was not possible due to the very low
malaria prevalence and the active case detection used in
this study covering a huge and largely inaccessible catch-
ment area.
Conclusion
Results from this study indicate that all samples harbour
at least one mutation on the pfdhfr and pfdhps genes
involved in SP resistance, and the predominant mutation
genotype consists of a combination of 59arg + 108asn +
164le + 437gly + 581gly (41.94%). There is every indication
that these genotypes confer high levels of resistance to SP
in the region. This strong evidence of the high prevalenceof mutations at the pfdhfr and pfdhps genes in Kalabakan
highlights an urgent need for similar studies in other
malaria-endemic areas in Sabah to provide urgently
needed data on the current situation of SP resistance in
the region.
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